Spring Bank Pharmaceuticals, Inc. (SBPH) financial statements (2021 and earlier)

Company profile

Business Address 35 PARKWOOD DRIVE
CAMBRIDGE, CB22 3AT
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1954485125
Cash and cash equivalents1929152411
Short-term investments 26332714
Receivables0    
Prepaid expense1    
Other undisclosed current assets64211
Total current assets:2658495126
Noncurrent Assets
Operating lease, right-of-use asset33
Property, plant and equipment12211
Long-term investments and receivables  17 1
Long-term investments  17 1
Intangible assets, net (including goodwill)34    
Goodwill15    
Intangible assets, net (excluding goodwill)19    
Restricted cash and investments 000 
Other noncurrent assets00000
Total noncurrent assets:3852011
TOTAL ASSETS:6463695227
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities145444
Accounts payable52222
Accrued liabilities92232
Interest and dividends payable 0   
Deferred revenue0 
Debt 0   
Business combination, contingent consideration, liability2    
Other undisclosed current liabilities1    
Total current liabilities:175444
Noncurrent Liabilities
Long-term debt and lease obligation33   
Operating lease, liability33
Liabilities, other than long-term debt00000
Other liabilities 0000
Business combination, contingent consideration, liability0    
Other undisclosed noncurrent liabilities1199136
Total noncurrent liabilities:4229136
Total liabilities:2128131810
Stockholders' equity
Stockholders' equity attributable to parent4336563517
Common stock00000
Additional paid in capital9116215811469
Accumulated other comprehensive loss(1)(0)(0)(0)(0)
Accumulated deficit(47)(126)(102)(79)(52)
Total stockholders' equity:4336563517
TOTAL LIABILITIES AND EQUITY:6463695227

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenue, net 0
Gross profit:11   0
Operating expenses(34)(33)(28)(21)(20)
Operating loss:(22)(33)(28)(21)(19)
Nonoperating income (expense)(1)1100
Investment income, nonoperating 1100
Other nonoperating expense(1)    
Interest and debt expense (1)   
Other undisclosed loss from continuing operations before equity method investments, income taxes(2)    
Loss from continuing operations before income taxes:(26)(32)(27)(21)(19)
Income tax benefit0    
Loss before gain (loss) on sale of properties:(26)(32)(27)(21)(19)
Other undisclosed net income 85  
Net loss:(26)(24)(23)(21)(19)
Other undisclosed net income (loss) attributable to parent   (7)2
Net loss attributable to parent:(26)(24)(23)(28)(17)
Other undisclosed net loss available to common stockholders, basic  (5)  
Net loss available to common stockholders, basic:(26)(24)(27)(28)(17)
Interest on convertible debt1    
Net loss available to common stockholders, diluted:(25)(24)(27)(28)(17)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(26)(24)(23)(21)(19)
Comprehensive loss:(26)(24)(23)(21)(19)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1(0)0(7)2
Comprehensive loss, net of tax, attributable to parent:(25)(24)(23)(28)(17)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: